<DOC>
	<DOCNO>NCT00331864</DOCNO>
	<brief_summary>Ranibizumab humanise recombinant monoclonal antibody fragment target human vascular endothelial growth factor A . This study ass safety efficacy ranibizumab administer as-needed dose regimen patient subfoveal choroidal neovascularization ( CNV ) secondary age-related macular degeneration ( AMD ) .</brief_summary>
	<brief_title>SUSTAIN - Study Ranibizumab Patients With Subfoveal Choroidal Neovascularization Secondary Age-Related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Patients participate study include complete participation study CRFB002A2301 ( ANCHOR ; NCT00061594 ) , newly diagnose patient , well previously diagnose patient recent disease progression . Male female patient &gt; 50 year age Diagnosis active primary recurrent CNV secondary AMD , include predominantly classic , minimally classic occult lesion classic component The total area CNV ( include classic occult component ) encompass within lesion must &gt; = 50 % total lesion area The total lesion area must &lt; = 12 disc area Patients BCVA ( best correct visual acuity ) score 73 24 letter , inclusive , study eye use ETDRSlike ( Early Treatment Diabetic Retinopathy Study ) grade chart ( approximately 20/40 20/320 ) Patients BCVA &lt; 34 letter eye ( legally blind defined bilateral vision 20/200 less 34 letter ) Laser photocoagulation , treatment intravitreal steroid , verteporfin photo dynamic therapy pegaptanib sodium study eye within 30 day precede Day 1 Previous participation clinical trial ( either eye ) involve antiangiogenic drug ( pegaptanib , ranibizumab , anecortave acetate , protein kinase C inhibitor , etc . ) Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>AMD , ranibizumab</keyword>
</DOC>